|
GB202102106D0
|
|
Anti-viral compositions
|
|
GB202102105D0
|
|
Prognostic method
|
|
GB202012298D0
|
|
Anti-viral therapy
|
|
GB202010268D0
|
|
Nail formulations and treatment regimes
|
|
WO2020079186A1
|
|
Dosage regime
|
|
IL263540D0
|
|
Microparticles comprising a sulphur-containing compound
|
|
CA3021344A1
|
|
Dosage regime
|
|
WO2018224813A1
|
|
Use of cysteamine compositions
|
|
US2018344671A1
|
|
Cysteamine as Neutrophil Elastase Inhibitor
|
|
US2017348254A1
|
|
Microparticles
|
|
WO2017212239A1
|
|
Treatment of drug-resistant microbial infections
|
|
GB201708965D0
|
|
Uses of cysteamine compositions
|
|
US2017348381A1
|
|
Formulation
|
|
GB201621447D0
|
|
Use
|
|
GB201609925D0
|
|
Formulation
|
|
GB201609940D0
|
|
Microparticles
|
|
GB201609921D0
|
|
Use
|
|
GB201601191D0
|
|
Culture medium
|
|
US2016106689A1
|
|
Use
|
|
US2016102052A1
|
|
Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
|
